Impact of psilocybin on cognitive function: A systematic review

被引:6
作者
Meshkat, Shakila [1 ]
Tello-Gerez, Triana Juliana [1 ]
Gholaminezhad, Fatemeh [1 ]
Dunkley, Benjamin T. [2 ,3 ]
Reichelt, Amy C. [4 ,5 ]
Erritzoe, David [6 ]
Veremetten, Eric [7 ]
Zhang, Yanbo [8 ]
Greenshaw, Andrew [8 ]
Burback, Lisa [8 ,9 ]
Winkler, Olga [8 ,9 ]
Jetly, Rakesh [10 ]
Mayo, Leah M. [11 ]
Bhat, Venkat [1 ,12 ,13 ]
机构
[1] Unity Hlth Toronto, St Michaels Hosp, Intervent Psychiat Program, Toronto, ON, Canada
[2] Hosp Sick Children, Neurosci & Mental Hlth, Res Inst, Toronto, ON, Canada
[3] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[4] Western Univ, Dept Physiol & Pharmacol, London, ON, Canada
[5] Univ Adelaide, Sch Biomed, Adelaide Med Sch, Adelaide, SA, Australia
[6] Imperial Coll London, Ctr Psychedel Res, Dept Brain Sci, London, England
[7] Leiden Univ, Dept Psychiat, Med Ctr, Leiden, Netherlands
[8] Univ Alberta, Dept Psychiat, Edmonton, AB, Canada
[9] Univ Alberta, Neurosci & Mental Hlth Inst NMHI, Edmonton, AB, Canada
[10] Univ Ottawa, Royal Ottawa Hosp, Inst Mental Hlth Res, Ottawa, ON, Canada
[11] Univ Calgary, Hotchkiss Brain Inst, Mathison Ctr Mental Hlth Res & Educ, Dept Psychiat, Calgary, AB, Canada
[12] Unity Hlth Toronto, St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada
[13] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
cognition; cognitive function; psilocybin; psychedelics; systematic review; 5-HT2A AGONIST PSILOCYBIN; HEALTHY HUMANS; MEMORY; RECOGNITION; PERFORMANCE; EXPERIENCES; PERCEPTION; ATTENTION; BEHAVIOR; PLACEBO;
D O I
10.1111/pcn.13741
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Psilocybin is a classic psychedelic with demonstrated preliminary clinical efficacy in a range of psychiatric disorders. Evaluating the impact of psilocybin on cognitive function is essential to unravel its potential benefits and risks. In this systematic review, we assessed psilocybin's effect on cognitive function through a comprehensive search of electronic databases from inception to January 2024, identifying 20 articles involving 2,959 participants. While 85% of studies were conducted in healthy volunteers, most of these studies (85%) used macrodoses, ranging from 45 mu g/kg to 30 mg/70 kg. Various cognitive aspects were evaluated and yielded mixed results. Global cognitive function, and processing speed remained mostly unchanged in healthy individuals; However, a limited number of studies reported improvements in certain areas such as sustained attention, working memory, and executive function especially in patients with treatment-resistant depression (TRD). Emotional processing was positively modified, particularly in TRD patients. Psilocybin was observed to enhance emotional empathy without significantly altering cognitive empathy and social cognition. Cognitive flexibility and creative cognition were noted to initially decline but could potentially improve over time. Additionally, with respect to learning and memory skills, psilocybin showed promise in improving specific memory types such as semantic associations and associative learning, while its effects on episodic and verbal memory have been less pronounced compared to other cognitive enhancers. The observed mixed findings underscore the complexity of psilocybin's cognitive influence. Further research is essential to provide a clearer understanding of psilocybin's impact on cognitive domains and to guide the development of safe and effective interventions.
引用
收藏
页码:744 / 764
页数:21
相关论文
共 65 条
[51]   The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation [J].
Rucker, James J. ;
Marwood, Lindsey ;
Ajantaival, Riikka-Liisa J. ;
Bird, Catherine ;
Eriksson, Hans ;
Harrison, John ;
Lennard-Jones, Molly ;
Mistry, Sunil ;
Saldarini, Francesco ;
Stansfield, Susan ;
Tai, Sara J. ;
Williams, Sam ;
Weston, Neil ;
Malievskaia, Ekaterina ;
Young, Allan H. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2022, 36 (01) :114-125
[52]   Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: Focus groups, online survey, proposed recommendations and their implementation [J].
Savović J. ;
Weeks L. ;
Sterne J.A.C. ;
Turner L. ;
Altman D.G. ;
Moher D. ;
Higgins J.P.T. .
Systematic Reviews, 3 (1)
[53]   Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo [J].
Shao, Ling-Xiao ;
Liao, Clara ;
Gregg, Ian ;
Davoudian, Pasha A. ;
Savalia, Neil K. ;
Delagarza, Kristina ;
Kwan, Alex C. .
NEURON, 2021, 109 (16) :2535-+
[54]   Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame [J].
Sloshower, Jordan ;
Guss, Jeffrey ;
Krause, Robert ;
Wallace, Ryan M. ;
Williams, Monnica T. ;
Reed, Sara ;
Skinta, Matthew D. .
JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE, 2020, 15 :12-19
[55]   Increased activation of indirect semantic associations under psilocybin [J].
Spitzer, M ;
Thimm, M ;
Hermle, L ;
Holzmann, P ;
Kovar, KA ;
Heimann, H ;
GouzoulisMayfrank, E ;
Kischka, U ;
Schneider, F .
BIOLOGICAL PSYCHIATRY, 1996, 39 (12) :1055-1057
[56]   THE SEROTONERGIC SYSTEM AND COGNITIVE FUNCTION [J].
Strac, Dubravka Svob ;
Pivac, Nela ;
Muck-Seler, Dorotea .
TRANSLATIONAL NEUROSCIENCE, 2016, 7 (01) :35-49
[57]   Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression [J].
Stroud, J. B. ;
Freeman, T. P. ;
Leech, R. ;
Hindocha, C. ;
Lawn, W. ;
Nutt, D. J. ;
Curran, H. V. ;
Carhart-Harris, R. L. .
PSYCHOPHARMACOLOGY, 2018, 235 (02) :459-466
[58]   Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies [J].
Studerus, Erich ;
Kometer, Michael ;
Hasler, Felix ;
Vollenweider, Franz X. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (11) :1434-1452
[59]  
Trivedi J K, 2006, Indian J Psychiatry, V48, P10, DOI 10.4103/0019-5545.31613
[60]   Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task:: Implications for the neuropharmacology of cognitive deficits in schizophrenia [J].
Umbricht, D ;
Vollenweider, FX ;
Schmid, L ;
Grübel, C ;
Skrabo, A ;
Huber, T ;
Koller, R .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (01) :170-181